



HIV/TB Research Frontiers meeting

Hosted by the World Health Organization and the Consortium to Respond to the AIDS/TB Epidemic (CREATE) on behalf of the TB/HIV Working Group of the Stop TB Partnership
February 16, 2010
San Francisco, USA

Draft Agenda

Co-Chairs: A. Grant and K. Castro

Part I: Isoniazid preventive therapy, mortality and other issues

11:30-11:35: Introduction and objectives of the meeting

Diane Havlir, WHO TB/HIV Working Group and UCSF

11:35-11:45: IPT and mortality of PLHIV: evidence from India.

Soumya Swaminathan, India

11:45-11:55 IPT and mortality of PLHIV: evidence from South Africa

Craig Innes, South Africa

11:55-12:05: IPT and mortality of PLHIV: evidence from BOTUSA trial, Botswana

Taraz Samandari, CDC

Commentary (5 minutes)

R. Chaisson, CREATE and John Hopkins University

12:10-12:40 Discussion - where we should go from here?

Part II: Isoniazid preventive therapy: implementation issues

12:40 -12:50: IPT in the context of TB screening: outcome of primary patient meta-analysis

Haileyesus Getahun, Stop TB Department, WHO.

12:50-13:00 IPT in higher MDR settings: what do we know and what could be done?

Alison Grant, LSTHM, UK

Commentary (5 minutes): TBD

13:05-13:25:Discussion

13:25-13:30: General conclusion and next steps

Diane Havlir, WHO TB/HIV Working Group and UCSF